New inhaled drug aims to help patients with lung scarring and high blood pressure
NCT ID NCT07181382
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests an inhaled drug called seralutinib for people with pulmonary hypertension (high blood pressure in the lungs) caused by interstitial lung disease (lung scarring). About 480 adults will receive either seralutinib or a placebo for 24 weeks, followed by a long-term safety extension. The main goal is to see if the drug improves how far patients can walk in six minutes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- seralutinib (inhaled powder)
- What this could lead to
- If it works, this could offer a new treatment option to improve exercise ability and slow worsening for people with pulmonary hypertension due to lung scarring.
- What could go wrong
- This trial is suspended, so results are uncertain. Even if effective, it may only help a subset of patients and side effects from the drug or inhaler are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hillel Yaffe Medical Center
Hadera, Israel
-
Pulmonary Associates of Richmond, Inc.
Richmond, Virginia, 23230, United States
-
University of New Mexico Health Sciences Center
Albuquerque, New Mexico, 87131, United States
-
Valley Advanced Lung Diseases Institute
Fresno, California, 93720, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Home workouts could ease breathing in rare lung condition
- New inhaled drug aims to ease lung scarring and heart strain
- New inhaled powder for lung blood pressure condition tested in 80 patients
- New combo therapy for lung scarring and high blood pressure under study
- New drug APL-9796 tested for lung blood pressure disorder
- Inhaled drug tested for long-term safety in lung-related high blood pressure